Airbus Launches Airspace Link HBCplus – The Flexible High Bandwidth Connectivity Solution for Airlines
Airbus has launched Airspace Link HBCplus, its new flexible satellite connectivity solution that will be offered as an SFE* line-fit catalogue option and also for retrofit on all Airbus programmes. HBCplus, which initially encompasses Ka-band services, will enable airlines to connect to a choice of Managed Service Providers (MSPs) via a new certified terminal and radome built as part of the aircraft. In the future it is planned to extend HBCplus to include MSPs which offer Ku-band services.
Andre Schneider, Airbus VP Cabin & Cargo Programme said: “We are excited to offer airlines a new connectivity service solution that will provide improved speed and reliability for passenger experience and more flexibility. Together with our leading industry partners we are pleased to enable future connectivity business opportunities in the context of the Airspace Link open ecosystem.”
To this end Airbus has selected connectivity satcom leader Inmarsat as the first MSP, contributing its GX Aviation inflight broadband solution which offers reliable and seamless passenger experience with global coverage and capacity for future growth. Additional MSPs will join the HBCplus offering in due course.
Philippe Carette, President of Inmarsat Aviation, said: “We are honoured that Airbus has chosen Inmarsat as the first Managed Service Provider for this transformative connectivity catalogue solution and is putting its trust in our award-winning GX Aviation service across all of its aircraft programmes. Inmarsat looks forward to working closely with our partners Airbus and SPI to deliver continuous innovation for airlines and their passengers worldwide.”
Meanwhile Safran Passenger Innovations (SPI) has been selected as the terminal provider and hardware integrator of ThinKom’s proven antenna technology - targeted for Ka-band services which delivers high data throughput and reliability combined with aircraft fuel savings thanks to the antenna’s lower drag radome.
Matt Smith, CEO, Safran Passenger Innovations, said: “Safran Passenger Innovations is delighted to be selected as the equipment supplier for Airbus’ Airspace Link connectivity solution. We are excited to be a part of the next evolution in the IFC industry by providing the technology for airlines to select the connectivity services most suited to their needs. We look forward to working with Airbus and our partners on this industry-changing endeavour.”
Airspace Link HBCplus thus provides satcom based off-board connectivity for the Airspace Link open ecosystem representing an end-to-end Airbus offer. This solution, which enables the exchange of data as one seamlessly integrated aircraft system, is ideally positioned to unlock future digital services capacity and demand growth, allowing airlines to deliver a best in class passenger connectivity experience, in an exponentially growing market.
SFE* = Supplier Furnished Equipment
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005572/en/
Contact information
Martin FENDT
Airbus
+33 (0)6 29 54 27 03 martin.fendt@airbus.com
Lois BENQUET
Airbus
+33 (0)6 42 88 10 65 lois.benquet@arbus.com
Jared SIQUELAND
Safran Passenger Innovations
+1 714 203 0525 jared.siqueland@zii.aero
Robeel HAQ
Inmarsat Aviation
+44 (0)207 728 1352 robeel.haq@inmarsat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom